112 related articles for article (PubMed ID: 27085562)
1. Association of AKR1C3 Polymorphisms with Bladder Cancer.
Tiryakioglu NO; Tunali NE
Urol J; 2016 Apr; 13(2):2615-21. PubMed ID: 27085562
[TBL] [Abstract][Full Text] [Related]
2. Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes.
Figueroa JD; Malats N; García-Closas M; Real FX; Silverman D; Kogevinas M; Chanock S; Welch R; Dosemeci M; Lan Q; Tardón A; Serra C; Carrato A; García-Closas R; Castaño-Vinyals G; Rothman N
Carcinogenesis; 2008 Oct; 29(10):1955-62. PubMed ID: 18632753
[TBL] [Abstract][Full Text] [Related]
3. Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?
Karunasinghe N; Zhu Y; Han DY; Lange K; Zhu S; Wang A; Ellett S; Masters J; Goudie M; Keogh J; Benjamin B; Holmes M; Ferguson LR
BMC Urol; 2016 Aug; 16(1):48. PubMed ID: 27485119
[TBL] [Abstract][Full Text] [Related]
4. Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients.
Voon PJ; Yap HL; Ma CY; Lu F; Wong AL; Sapari NS; Soong R; Soh TI; Goh BC; Lee HS; Lee SC
Br J Clin Pharmacol; 2013 Jun; 75(6):1497-505. PubMed ID: 23116553
[TBL] [Abstract][Full Text] [Related]
5. Variation in genes encoding the neuroactive steroid synthetic enzymes 5α-reductase type 1 and 3α-reductase type 2 is associated with alcohol dependence.
Milivojevic V; Kranzler HR; Gelernter J; Burian L; Covault J
Alcohol Clin Exp Res; 2011 May; 35(5):946-52. PubMed ID: 21323680
[TBL] [Abstract][Full Text] [Related]
6. Association analysis between the polymorphisms of HSD17B5 and HSD17B6 and risk of polycystic ovary syndrome in Chinese population.
Ju R; Wu W; Fei J; Qin Y; Tang Q; Wu D; Xia Y; Wu J; Wang X
Eur J Endocrinol; 2015 Mar; 172(3):227-33. PubMed ID: 25422294
[TBL] [Abstract][Full Text] [Related]
7. A novel polymorphism in the 17beta-hydroxysteroid dehydrogenase type 5 (aldo-keto reductase 1C3) gene is associated with lower serum testosterone levels in caucasian men.
Jakobsson J; Palonek E; Lorentzon M; Ohlsson C; Rane A; Ekström L
Pharmacogenomics J; 2007 Aug; 7(4):282-9. PubMed ID: 16983398
[TBL] [Abstract][Full Text] [Related]
8. Maternal and offspring genetic variants of AKR1C3 and the risk of childhood leukemia.
Liu CY; Hsu YH; Pan PC; Wu MT; Ho CK; Su L; Xu X; Li Y; Christiani DC;
Carcinogenesis; 2008 May; 29(5):984-90. PubMed ID: 18339682
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix.
Wu CH; Ko JL; Chen SC; Lin YW; Han CP; Yang TY; Chien MH; Wang PH
Gynecol Oncol; 2014 Feb; 132(2):474-82. PubMed ID: 24316309
[TBL] [Abstract][Full Text] [Related]
10. Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor.
Azzarello JT; Lin HK; Gherezghiher A; Zakharov V; Yu Z; Kropp BP; Culkin DJ; Penning TM; Fung KM
Int J Clin Exp Pathol; 2009 Nov; 3(2):147-55. PubMed ID: 20126582
[TBL] [Abstract][Full Text] [Related]
11. In vitro CAPE inhibitory activity towards human AKR1C3 and the molecular basis.
Li C; Zhao Y; Zheng X; Zhang H; Zhang L; Chen Y; Li Q; Hu X
Chem Biol Interact; 2016 Jun; 253():60-5. PubMed ID: 27163852
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.
Liu C; Armstrong CM; Lou W; Lombard A; Evans CP; Gao AC
Mol Cancer Ther; 2017 Jan; 16(1):35-44. PubMed ID: 27794047
[TBL] [Abstract][Full Text] [Related]
13. Variation in AKR1C3, which encodes the neuroactive steroid synthetic enzyme 3α-HSD type 2 (17β-HSD type 5), moderates the subjective effects of alcohol.
Milivojevic V; Feinn R; Kranzler HR; Covault J
Psychopharmacology (Berl); 2014 Sep; 231(17):3597-608. PubMed ID: 24838369
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-10 G-1082A and C-819T polymorphisms as possible molecular markers of urothelial bladder cancer.
Ahirwar D; Mandhani A; Mittal RD
Arch Med Res; 2009 Feb; 40(2):97-102. PubMed ID: 19237018
[TBL] [Abstract][Full Text] [Related]
15. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
[TBL] [Abstract][Full Text] [Related]
17. Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand.
Karunasinghe N; Symes E; Gamage A; Wang A; Murray P; Zhu S; Goudie M; Masters J; Ferguson LR
PLoS One; 2019; 14(5):e0217373. PubMed ID: 31125365
[TBL] [Abstract][Full Text] [Related]
18. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
19. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
[TBL] [Abstract][Full Text] [Related]
20. Aldo-keto reductase 1C3 is expressed in differentiated human epidermis, affects keratinocyte differentiation, and is upregulated in atopic dermatitis.
Mantel A; Carpenter-Mendini AB; Vanbuskirk JB; De Benedetto A; Beck LA; Pentland AP
J Invest Dermatol; 2012 Apr; 132(4):1103-10. PubMed ID: 22170488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]